Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - iron sucrose - solution for injection - 20mg/1ml

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - iron sucrose - solution for injection - 20mg/1ml

Australia - inglese - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ferric carboxymaltose -

Australia - inglese - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - iron polymaltose -

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - solution for injection/infusion - 20 milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

Australia - inglese - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ulipristal acetate -

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - ulipristal acetate 5mg - tablet - 5 mg - active: ulipristal acetate 5mg excipient: croscarmellose sodium magnesium stearate mannitol microcrystalline cellulose purified talc - ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Stati Uniti - inglese - NLM (National Library of Medicine)

vifor (international) inc. - epoetin (unii: 64fs3bfh5w) (epoetin - unii:64fs3bfh5w) - retacrit is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and not on dialysis to decrease the need for red blood cell (rbc) transfusion. retacrit is indicated for the treatment of anemia due to zidovudine administered at ≤ 4,200 mg/week in patients with hiv-infection with endogenous serum erythropoietin levels of ≤ 500 munits/ml. retacrit is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. retacrit is indicated to reduce the need for allogeneic rbc transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dl who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. retacrit is not indicated for patients who are willing to donate autologous blood pre-operatively. retacrit has not been shown to improv

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - ferric carboxymaltose - solution for injection - 50mg/1ml